Table 6.
Treatment alteration types guided by bone biopsy results.
| Major Treatment Alteration Types in Patients (May be More than One Per Patient), n (%) | 68 |
|---|---|
| Addition of Medication(s) | 38 (55.9) |
| Parathyroidectomy Surgery (For Renal Osteodystrophy with Hyperparathyroid Bone Disease) | 22 (32.4) |
| Genetic Testing/Consult | 9 (13.2) |
| Further Diagnostics | 8 (11.8) |
| Removal of Medication(s) and Addition of Medication(s) | 7 (10.3) |
| Added to VUMC Undiagnosed Disease Network | 3 (4.4) |
| Recruited to Clinical Trial | 1 (1.5) |
| Attempt to Correct Electrolyte Balances i.e., Magnesium | 1 (1.5) |
| Biopsy-directed Medication Additions (Throughout Follow-Up), FDA Approval Year | |
| Teriparatide, 2002 | 31 |
| Zoledronic Acid, 2001 | 10 |
| Denosumab, 2010 | 8 |
| Alendronate, 1995 | 4 |
| Pamidronate, 1991 | 4 |
| Calcitonin, 1991 | 1 |
| Romosozumab, 2019 | 3 |
| Abaloparatide, 2017 | 3 |
| Hormone Replacement Therapy, 1998 | 2 |
| Risedronate, 1998 | 1 |
| Asfotase Alfa, 2015 | 1 |
| Calcitriol, 1978 | 1 |